{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'ask him/her to indicate the response that best describes his/her experience. Pruritus assessed by', 'this evaluation should be reported as an AE only if therapy is required.', '8.2.4', 'Percent Body Surface Area with Active Congenital Ichthyosis in the', 'Treatment/Assessment Areas', 'The percent BSA with active CI within the Treatment Area will be calculated at Visit 1 (Screening).', 'The Treatment Area includes all affected skin excluding the hands, face, neck, scalp and genitalia.', 'This calculation is confirmed at Visit 2 (Baseline) and assessed at all follow-up visits. The', 'minimum affected area to be treated will be no less than 10% and no more than 90% of the whole', 'BSA at Visit 1 (Screening). In addition, the percent BSA with active CI within the designated VIIS', '/Assessment Areas will be calculated at Visit 1 (Screening) and at all follow-up visits. Note that', 'the Treatment Area is at least equal to or larger than the VIIS Assessment Area. Based on the', 'Treatment and VIIS Assessment Areas selected in a given subject and the extent of his/her disease,', 'these two areas may or may not be the same. Two examples are provided below for clarity:', 'Treatment Area', 'VIIS Assessment area', '% BSA', '% BSA', 'Subject 1', '90% (entire body', '24% (upper back,', 'minus hands, face,', 'upper arms, lower', 'neck, scalp, genitalia)', 'legs and dorsal feet)', 'Subject 2', '70%', '13% (upper back and', 'upper arms)', '8.2.5', 'Dermatology Life Quality Index', 'The DLQI (Dermatology Quality of Life Index), is a dermatology-specific Quality of Life', 'instrument. Age-appropriate DLQI will be completed at Visit 2 (Baseline), Visit 5, and Visit 6', '(EOS). The standard DLQI is a questionnaire designed for subjects > 16 years of age that measures', \"the impact of skin disease on the previous week's quality of life. There are 10 questions related to\", 'the following topics: symptoms, embarrassment, shopping and home care, clothes, social and', 'leisure, sport, work or study, close relationships, sex, treatment (see Appendix 9). Questions are', 'scored from 0 to 3 with a possible score range from 0 (no impact of skin disease on quality of life)', 'to 30 (maximum impact on quality of life). The score ranges are shown in Table 4.', 'Table 4', 'Dermatology Life Quality Index Scale', '0 to 1 =', \"No effect on patient's life\", '2 to 5 =', 'Small effect', '39']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', '6 to 10 =', 'Moderate effect', '11 to 20 =', 'Very large effect', '21 to 30 =', 'Extremely large effect.', 'The minimal clinically important difference (MCID) is the minimum difference in score that is', 'meaningful for a subject. This is considered 4 for inflammatory skin diseases.', \"Children's DLQI will be used for subjects < 16 years of age to measure the impact of skin disease\", \"on the previous week's quality of life. There are 10 questions related to the following topics:\", 'symptoms and feelings, leisure, school or holidays, personal relationships, sleep, treatment (see', 'Appendix 10). Questions are scored from 0 to 3 with a possible score range from 0 (no effect on', \"child's life) to 30 (extremely large effect). The score ranges are shown in Table 5.\", 'Table 5', \"Children's Dermatology Life Quality Index Scale\", '0 to 1 =', \"No effect on child's life\", '2 to 6 =', 'Small effect', '7 to 12 =', 'Moderate effect', '13 to 18 =', 'Very large effect', '19 to 30 =', 'Extremely large effect.', '8.3', 'Safety Assessments', 'The planned time points for all safety assessments are provided in the Schedule of Activities', '(Section 1.2).', '8.3.1', 'Physical Examinations', 'A brief physical examination will be performed at Visit 1 (Screening). Abbreviated examination/', 'subject disposition will be conducted at Visit 2 (Baseline) to identify any changes since the', 'Screening visit and at Visit 6 EOS to assess for any changes during the study. The examination', 'will evaluate head and neck, dermatological, cardiovascular, respiratory, gastrointestinal', '(abdomen), and gross motor and gait body assessments. Abnormalities at Visit 1 (Screening) and', 'Visit 2 (Baseline) prior to treatment will be recorded as medical history. Any new or worsening', 'abnormalities at Visit 6 (EOS) will be recorded as AEs.', '8.3.2', 'Vital Signs', 'Vital signs including temperature, systolic and diastolic blood pressure, heart rate, and respiration', 'rate will be measured at Visit 1 (Screening) and Visit 6 (EOS). Assessments will be made after the', 'subject has rested in a seated position for at least 5 minutes in a quiet setting without distractions', '(eg, television, cell phones). Height and weight will only be measured at Visit 1 (Screening).', '40']\n\n###\n\n", "completion": "END"}